Access cutting-edge multiple sclerosis treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access multiple sclerosis specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related multiple sclerosis treatment provided free
This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, and 24. At Month 24, participants will be randomized (2:1) to one of two Arms with randomized treatmen
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Check if you qualify for this multiple sclerosis clinical trial in New York, NY
If you're searching for multiple sclerosis treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.